engleski

Pentadecapeptide BPC 157 Has a Positive Effect on NSIAAs Lesions and Acute and Chronic Inflammatory Lesions.

Besides a superior protection of the pentadecapeptide BPC 157 (an essential fragment of an organoprotective gastric juice peptide BPC) against different gastrointestinal and liver lesions, an acute anti-inflammatory and analgetic activity was also noted (1-8). For instance, pentadecapeptide BPC 157 administered either in ng or ug per kg range intraperitoneally, significantly reduced pain reaction in writhing (inflammatory and non-inflamatory, prostaglandin dependent and independent). consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesion was simultaneously studied in rats. In gastrointestinal lesion (indomethacin 30mg/kg s.c.), aspirin (400 mg/kg i.g.) and diclofenac (125 mg/kg i.p.) studies, BPC 157 (10 ug or 10 ng/kg i.p.) was regularly given simultaneously and/or one hour prior to drug application (indomethacin). In the adjuvant arthritis (tail-application of 0, 2 ml of Freund's adjuvant) studies (14 days, 30 days, one year) BPC 157 (10 ug or 10 ng/kg i.p.) it was given as a single application (at 1 hour either before or following the application of Freund's adjuvant) or in a once daily regiment (0-14th day, 14-30th day, 14th day-one year). Given with the investigated NSAIAs, BPC 157 consistently reduced the otherwise prominent lesions in the stomach of the control rats, as well as the lesions in the small intestine in the indomethacin groups. In the adjuvant arthritis studies, the lesions development seems to be considerably reduced after single pentadecapeptide medication, and even more attenuated in rats daily treated with BP 157. As a therapy of already established adjuvant arthritis, its salutary effect consistently appeared already after two weeks of medication and it could be cleary seen also after one year of application. Taking togather all of these results, these data likely point to a special inflammatory and mucosa integrity protective effect.

pentadecapeptide BPC 157; NSAIA;

nije evidentirano